STAT Plus: Safety concerns regarding Novartis’s new eye drug boost Regeneron stock
A leading association of eye doctors has warned its members about safety concerns about Novartis’s…
Category: biotechnology
STAT Plus: Alkermes sued over death of man who overdosed after taking addiction treatment Vivitrol
The parents of a 26-year-old California man who died of an opioid overdose have sued…
STAT Plus: With strong data on lead drug, Kadmon and CEO Harlan Waksal plot their redemption
Months and even years after a successful bone marrow transplant, when patients in remission finally…
.jpg)
STAT Plus: After 21-year journey, Esperion to test market for a cholesterol pill that is less expensive than some competitors
A new cholesterol-lowering medication manufactured by Esperion Therapeutics was approved by the Food and Drug…
STAT Plus: In a cramped Kendall Square, biotech startups sublet desks and squeeze into shared labs
Before it launched in January, biotech startup EQRx wasn’t quite large enough to justify leasing…
STAT Plus: FDA names genes that may interact with specific drugs, offering clarity to genetic testing industry
The burgeoning industry built around telling patients how their genes may interact with specific drugs…
STAT Plus: Biotech founder who said his painkiller would replace opioids sentenced to 7 years in prison
The founder of a biotech who said his company had developed a painkiller that would…
Opinion: Why we need mandatory labeling of GMO products
The conversation around genetic engineering and food is undermined by a lack of information that…
Watch: VCs have to predict the future. Here’s what three of them expect next in biotech
Biotech venture capitalists make their money by seeing the future better than most of us,…
STAT Plus: ‘Pharma doesn’t like fish oil’: Wall Street funds sold Amarin after big win with heart drug
Wall Street fund managers lightened their stock positions in Amarin (AMRN) during the fourth quarter…
STAT Plus: Microbiome-based drug makers are hoping new late-stage data will pull the field out of the shadows
The microbiome industry is on the cusp of a turning point. Seres Therapeutics, one of…
STAT Plus: A longtime health care investor recalls the insulin bong, praises discipline in valuations, and looks to South America
Les Funtleyder is a longtime health care investor who started his professional investing career just…
The Zolgensma lottery, billionaire philanthropy, & life on the buy side
What’s the right way to give drugs away? Is $3 billion even a lot of…
Weight-loss drug to be pulled from market after FDA expresses concerns on cancer risk
The Japanese drug maker Eisai on Thursday said it would withdraw the weight-loss drug Belviq…
Opinion: STAT Plus: Why medtech is a different beast than biotech in the life sciences pack
Biotech innovations dominate the life science news cycle — think CRISPR for gene editing or…
STAT Plus: U.S. biotechs fear the coronavirus outbreak will delay their China-based research
Biotech investors and executives are growing worried that restrictions intended to contain the coronavirus epidemic…
STAT Plus: With new combination drug data, Exelixis takes another shot at prostate cancer treatment
In 2014, the Bay Area biotech company Exelixis (EXEL) tried to develop a drug for…
STAT Plus: Investor impatience with Gilead reclamation project sparks acquisition chatter
In recent days, there’s been investor chatter about stalled-out Gilead Sciences (GILD) becoming a takeover…
STAT Plus: Beam Therapeutics raises $180 million in IPO
Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public…
Jeffrey Bluestone steps down as Parker Institute president to develop cell therapies for autoimmune diseases
Jeffrey Bluestone, the prominent immunologist, has decided to leave his position as president of the…
Sanofi reports positive results on multiple sclerosis drug licensed from Principia
The French drug giant Sanofi on Thursday reported positive results in a study of its…
Biogen wins patent challenge to key multiple sclerosis drug
A U.S. appeals panel on Wednesday denied a patent challenge against Biogen’s multiple sclerosis drug…
STAT Plus: This biotech just bought three failed drugs. Here’s why
Biopharma companies don’t usually buy experimental drugs that don’t work. But that’s exactly what CODA…
In the race to develop a coronavirus treatment, Regeneron thinks it has the inside track
TARRYTOWN, N.Y. — The novel coronavirus arrived at Regeneron Pharmaceuticals’ sprawling campus like any other…
.jpg)
STAT Plus: This VC firm once pledged to never invest in health care. Now it’s launching its third life sciences fund
Marc Andreessen, famous for proclaiming that software was “eating the world,” said in 2009 that…
If biotech had a Mount Rushmore, whose heads would you chisel in the granite?
If someone sculpted a Mount Rushmore of biotech CEOs, who’d be on it? The question…
STAT Plus: FDA approves the first treatment for peanut allergy, but commercial success is hardly assured
Children and teenagers with severe, sometimes life-threatening peanut allergies can reduce their risk from accidental…
STAT Plus: Watch: CEO Daniel O’Day says Gilead is in a ‘sweet spot.’ What’s next?
What’s Gilead going to buy? That’s the single, persistent question Daniel O’Day has faced in…
STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug
A European regulatory setback for a Bristol-Myers Squibb (BMY) blood-cancer drug could have a negative…
STAT Plus: As Biogen gets squishy on timing for an aducanumab filing, the clock is ticking
There are few things in this world more squishy than Wonder Bread. Exception: Biogen’s answers…
STAT Plus: Spring Bank scraps hepatitis R&D after patient dies in trial
Spring Bank Pharmaceuticals (SBPH) said Wednesday it was abandoning efforts to develop a drug to…
STAT Plus: In a pivot, Decibel Therapeutics loses its founding CEO — and some of its discovery programs
Decibel Therapeutics CEO Steven Holtzman is really, officially retiring. The departure of the longtime vet…
Three star scientists announce plan to solve biotech’s ‘missing women’ problem
They are the biotech equivalent of the “missing girls” in countries with a skewed gender…
STAT Plus: With new rules, FDA aims to spark competition, lower prices for expensive gene therapies
WASHINGTON — The Food and Drug Administration released a slew of gene therapy policies Tuesday…
STAT Plus: Biotech earnings preview: Unsettled investors hoping for strong 2020 outlooks
Biotech earnings season kicks off Thursday with fourth-quarter reports from Alexion Pharma (ALXN), Amgen (AMGN),…
STAT Plus: Acceleron pulmonary hypertension drug succeeds in mid-stage clinical trial
Acceleron Pharma said Monday that a mid-stage clinical trial involving an experimental drug for pulmonary…
STAT Plus: The suburbs are cheaper, but they don’t have what Kendall Square has for biotechs: serendipity
You know Kendall Square’s office rents have gotten stratospheric when a CEO compares the neighborhood…
STAT Plus: ‘The gurus of sperm’: Ohana Biosciences is taking a different approach to fertility
“Ohana” means family in Hawaiian — and the new Cambridge, Mass.-based biotech that took that…
How fast can biotech come up with a vaccine for the latest outbreak?
The deadly outbreak of a novel coronavirus has sparked a race among biotech companies, each…
Listen: The latest on the China virus, Sarepta’s ongoing FDA saga, and biotech at Davos
Are we dealing with a SARS redux? Has the FDA lost its teeth? And what…
STAT Plus: The FDA continues to struggle with the implications of approving Sarepta’s drugs
New documents released Wednesday lay bare the stark divide within the Food and Drug Administration…
STAT Plus: How swallowing a star might keep you from missing a dose of medicine
SAN FRANCISCO — Plenty of drug industry executives who take over this city for a…
The truth about JPM: Less is more
SAN FRANCISCO — Yet another J.P. Morgan Healthcare Conference is done. Was it worth it?…
Listen: A J.P. Morgan recap, a plan to bust pharma monopolies, and a website for cancer patients
Why weren’t there any big deals announced this week? What does the word “equivalar” mean?…
STAT Plus: A venture firm warms to funding neuroscience
Longtime venture capital star Beth Seidenberg and former Amgen R&D chief Sean Harper say they…
STAT Plus: Startup Spotlight: With a different method for gene therapy, Generation Bio eyes an IPO
Seven years ago, one of Generation Bio’s scientific founders couldn’t convince any top-tier journals to…
STAT Plus: AstraZeneca fish oil drug fails, leaving Amarin as last drug standing
AstraZeneca (AZN) said Monday that it would stop a large clinical study of a fish-oil-derived…
STAT Plus: Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline
Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for…
Opinion: Welcome to the bioengineering culture clash
Bioengineering, once viewed primarily as an academic discipline, is growing up. Our ability to engineer…
Listen: Biohacker Josiah Zayner on getting canceled, good news in cancer, and a long road in Ebola
Does pharma deserve more credit? Will history forgive He Jiankui? And how does a laboratory…